Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Dermavant licenses cerdulatinib from Portola for topical applications

Published 22 December 2016

Dermavant Sciences has signed an exclusive worldwide licensing agreement with Portola Pharmaceuticals for the development and commercialization of cerdulatinib in topical applications beyond oncology.

Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients with resistant or relapsed hematologic cancer.

Cerdulatinib is currently being investigated in an ongoing Phase 2a trial in patients with relapsed/refractory B-cell malignancies who have failed multiple therapies. Under the terms of the agreement with Dermavant, Portola retains full rights to all non-topical formulations of cerdulatinib, including oral formulations.

Dermavant, a subsidiary of Roivant Sciences, intends to pursue the clinical development of cerdulatinib as a topical therapy for a variety of dermatologic conditions.

Dermavant believes that the profile of cerdulatinib is ideal for development in these skin diseases where a growing body of evidence suggests that both JAK and Syk are important drivers of disease manifestation.

Dermavant chief medical officer Jim Lee, MD, PhD said: “The addition of cerdulatinib to our pipeline renders Dermavant an emerging leader in medical dermatology.

“Given the anti-inflammatory properties associated with both JAK and Syk inhibition we look forward to advancing the clinical development of cerdulatinib as a potential therapy for a number of dermatologic conditions with significant unmet need.”

Appointment of Dr. Jim Lee as Chief Medical Officer

Dermavant’s Chief Medical Officer, Dr. Jim Lee, brings over 17 years of experience in successfully developing multiple therapies across various indications in the field of dermatology. Most recently he served as Vice President, Global Head of Clinical Development at Stiefel Laboratories from 2011 to 2016.

Dr. Lee previously served as Chief Medical Officer at Graceway Pharmaceuticals and Director of Immunology at Centocor. Dr. Lee received his MD and PhD in Biochemistry and Molecular Biology from the University of Illinois College of Medicine.



Source: Company Press Release